#CDMO India

[octanexlabsin]

As a growing organization, we collaborate and work in unison with a large number of reputed and like-minded partners and clients who can nourish our aspirations. We commit to quality and superior standards in all areas of our operations. It has wide range of products and compounds for Pharma, Agro, Fine and Specialty Chemicals, CRO and CDMO sectors. 

[neosciencehub]

The Rise of India’s Pharmaceutical Industry: A Vision for 2047

The Rise of India’s Pharmaceutical Industry: A Vision for 2047 @neosciencehub #India #PharmaceuticalIndustry #2047 #API #CDMO #neosciencehub #Pharmanews

India’s pharmaceutical industry stands at a pivotal crossroads, with the potential to become a global leader in the coming decades. With a reputation as the “pharmacy of the world,” India currently supplies nearly 20% of global generic medicines, filling an essential role in healthcare systems around the globe. However, as the industry evolves, it faces the dual challenge of capitalizing on its…

[chemxpert]

Explore Global Pharma Innovations with Chemxpert Database

Discover the latest advancements in pharma exhibitions with Chemxpert Database, your go-to resource for insights into the food and drug sectors. Whether you're exploring the pharmaceutical preparation process, capsule manufacturing techniques, or seeking contract manufacturing companies in India, Chemxpert delivers a comprehensive view. Connect with top-tier pharmaceutical companies in Russia and the best pharma companies worldwide. Find a trusted pharmaceutical manufacturing company near you and stay updated with Chemxpert’s vast database.

[medicinemanufacturing]

How CDMO Pharma Companies Accelerate Drug Development and Manufacturing

Introduction

The pharmaceutical landscape is increasingly complex, and bringing a drug from concept to market involves various stages, requiring specialised expertise. CDMO pharma companies (Contract Development and Manufacturing Organisations) have become essential partners, helping pharmaceutical firms streamline drug development and production. By providing both development and manufacturing services, CDMO pharma companies help accelerate time to market, ensure regulatory compliance, and reduce costs.

With trusted partners like Prakruti Life Science, pharmaceutical companies can focus on core research activities. At the same time, CDMOs handle everything from initial formulation to large-scale manufacturing of critical products, such as Aceclofenac Thiocolchicoside tablets and Rabeprazole domperidone capsules. This blog will explore how CDMO pharma companies contribute to accelerating drug development and manufacturing.

What Are CDMO Pharma Companies?

A CDMO pharma company is a third-party organisation that provides comprehensive drug development and manufacturing services. These companies typically offer services from the early stages of drug formulation to clinical trials, regulatory approvals, and large-scale manufacturing.

For pharmaceutical companies, especially smaller firms without extensive manufacturing capabilities, CDMOs are valuable partners in efficiently bringing a drug to market. For instance, Prakruti Life Science offers expertise in producing complex formulations such as Thiocolchicoside capsules, helping streamline the production process while ensuring high-quality standards.

The Role of CDMO Pharma Companies in Drug Development

The role of CDMO pharma companies extends far beyond just manufacturing. They are integral to the entire drug development process, contributing in the following key areas:

1. Formulation Development

One of the first steps in drug development is formulating the active pharmaceutical ingredient (API) into a stable, effective, and safe product. CDMO pharma companies are experts in developing formulations that meet stringent regulatory requirements while maximising the drug’s bioavailability and efficacy. For example, Aceclofenac paracetamol tablets, a common pain-relief medication, require careful formulation to balance its anti-inflammatory and analgesic effects.

2. Clinical Trials and Testing

After formulation, CDMO pharma companies oversee the clinical trial phases, ensuring that the drug meets safety and efficacy standards. Their involvement helps pharmaceutical companies navigate the regulatory landscape, ensuring the drug complies with international guidelines before entering the market.

3. Scaling Up Manufacturing

Once a drug has passed clinical trials and gained regulatory approval, the next step is scaling up production. CDMO pharma companies have the infrastructure to move from small-scale production to large-scale manufacturing without compromising quality. This is particularly crucial for drugs like Rabeprazole domperidone capsules, which require consistent output at high volumes to meet global demand.

How CDMO Pharma Companies Accelerate Drug Development

Partnering with CDMO pharma companies significantly accelerates drug development, allowing pharmaceutical firms to bring their products to market faster. Here’s how:

1. Reducing Time to Market

The traditional drug development process can take years, but CDMO pharma companies help reduce this timeline by offering an integrated approach. Combining development and manufacturing services eliminates the need for multiple vendors and reduces delays associated with switching between service providers. This seamless transition from development to production ensures that drugs like Aceclofenac Thiocolchicoside tablets reach patients faster.

2. Access to Advanced Technology

CDMOs often invest in cutting-edge technology and equipment to stay competitive in the industry. Pharmaceutical companies that partner with CDMOs gain access to these advanced capabilities without the need for substantial in-house investments. This is particularly beneficial when dealing with complex formulations, such as Thiocolchicoside capsules, where precision and technology are critical for ensuring efficacy and stability.

3. Expertise in Regulatory Compliance

Navigating the intricate regulatory landscape is one of the biggest challenges in drug development. CDMO pharma companies specialise in regulatory compliance, ensuring that every stage of the development and manufacturing process adheres to national and international standards. This expertise helps prevent costly delays and accelerates the drug’s approval process.

4. Flexible Manufacturing Solutions

As demand for pharmaceutical products fluctuates, CDMOs offer scalable solutions that allow pharmaceutical companies to adjust production volumes as needed. Whether it's increasing production for a popular drug like Rabeprazole domperidone capsules or scaling down for niche products, CDMOs provide the flexibility needed to meet market demands without significant disruptions.

Benefits of Partnering with CDMO Pharma Companies

Partnering with a CDMO pharma company offers several advantages for pharmaceutical firms looking to optimise their drug development and manufacturing processes.

1. Cost Efficiency

Setting up in-house manufacturing capabilities can be relatively inexpensive, especially for smaller pharmaceutical companies. CDMOs like Prakruti Life Science provide cost-effective alternatives by offering access to state-of-the-art manufacturing facilities without the overhead of owning and operating these resources.

2. Expertise Across Multiple Stages

CDMO pharma companies provide end-to-end services, allowing pharmaceutical companies to leverage their expertise across multiple stages of drug development. From formulation and testing to large-scale manufacturing, CDMOs offer a breadth of knowledge that simplifies the entire process.

3. Risk Mitigation

By outsourcing development and manufacturing to experienced CDMOs, pharmaceutical companies can mitigate risks associated with quality control, regulatory compliance, and production delays. CDMOs are well-versed in managing these challenges, ensuring that the final product meets all necessary standards.

4. Focus on Core Competencies

By outsourcing to CDMOs, pharmaceutical companies can concentrate on their core competencies, such as research and marketing. For instance, Prakruti Life Science helps pharmaceutical firms focus on innovation and market expansion while ensuring that critical medications like Aceclofenac paracetamol tablets are manufactured efficiently and compliant with regulatory standards.

Challenges in Working with CDMO Pharma Companies

While CDMO pharma companies offer many advantages, there are also challenges that pharmaceutical firms may face when working with them.

1. Communication and Collaboration

Effective communication between the pharmaceutical company and the CDMO ensures a successful partnership. Miscommunication can lead to production delays or issues with quality control. Establishing clear lines of communication and setting expectations upfront is essential.

2. Quality Assurance

Quality control is a shared responsibility between the pharmaceutical company and the CDMO. Both parties must ensure rigorous quality assurance protocols are in place to avoid any issues that may arise during manufacturing.

3. Intellectual Property Concerns

When outsourcing to a CDMO pharma company, pharmaceutical firms must protect their intellectual property (IP). While CDMOs are typically bound by confidentiality agreements, companies must take additional steps to safeguard their proprietary formulations and data.

Conclusion

CDMO pharma companies are essential partners in accelerating drug development and manufacturing, providing the expertise, technology, and scalability required to bring drugs to market quickly and efficiently. Through their integrated approach, CDMOs like Prakruti Life Science help pharmaceutical companies reduce time to market, ensure regulatory compliance, and manage costs.

With their ability to streamline everything from formulation to large-scale production, CDMO pharma companies allow pharmaceutical firms to focus on core research and marketing efforts while ensuring that critical medications, such as Thiocolchicoside capsules and Aceclofenac paracetamol tablets, are produced to the highest standards. As the pharmaceutical industry continues to evolve, the role of CDMO pharma companies will become increasingly important in meeting the growing demand for innovative and high-quality medicines.

[cdmocroserives]

[gland-pharma-limited]

Leading Injectable Pharmaceutical Company | Gland Pharma Limited

Gland Pharma Limited is a leading CDMO pharma company supplying Generic & complex injectables to India, USA , Europe, Canada, Australia, and the Rest of the world.

to know more visit: https://glandpharma.com/about

[sauravchemicals]

Get answers to key questions about analytical method validation, verification, and transfer in the pharmaceutical industry. Ensure accuracy and reliability.

[mysticalcrowntyphoon]

Role of CDMOs in Enhancing Syrup Formulations Taste for better patient acceptability

Table of content

Taste & Syrup Formulations

CDMOs and their  expertise

Akums Drug and  Pharmaceuticals Ltd.

Taste & Syrup Formulations

Enhancing syrup formulations' taste for better patient acceptability is required because the taste is an important factor in medication adherence. When a medication tastes unpleasant, patients are less likely to take it as prescribed, leading to poor treatment outcomes. Improving the taste of syrup formulations can encourage patients to take their medication as prescribed, improving medication compliance, and ultimately, patient outcomes. Additionally, improving the taste of syrup formulations can make it easier for patients, especially children, to swallow the medication. Many children find the taste of medications unpleasant, which can make it difficult for parents to administer the correct dosage. To address this issue, taste-masking technology has been developed to cover the bitter taste of medications and improve their palatability.

Thus, enhancing the taste of syrup formulations can lead to improved patient satisfaction, compliance, and health outcomes.

CDMOs and their expertise

CDMOs (Contract Development and Manufacturing Organizations) play a crucial role in enhancing syrup formulations' taste by utilizing their expertise and advanced technologies in drug formulation and delivery. They collaborate with pharmaceutical companies to create custom-tailored syrup formulations that cater to the specific needs of the patients, thereby improving their overall satisfaction and adherence to the medication regimen.

Some of the key ways in which CDMOs enhance syrup formulations' taste are:

·        Flavor and sweetener selection: CDMOs use their expertise in selecting the right combination of flavors and sweeteners to mask the bitter taste of drugs. This not only enhances the taste of the syrup but also improves its overall palatability.

·        Dosage form development: CDMOs develop and optimize the dosage form of the syrup, such as emulsions, suspensions, or solutions, to ensure the drug is evenly dispersed in the liquid and easy to swallow.

·        Packaging design: CDMOs help design innovative and user-friendly packaging that improves syrup taste and consumer convenience. For example, squeeze bottles or cups with markings can help measure dosage and improve the patient's experience.

·        Quality control: CDMOs ensure that the syrup formulation meets the highest quality standards and is safe for consumption. They conduct rigorous testing and validation and comply with regulatory requirements.

·        Continuous improvement: CDMOs work continuously to improve syrup formulations' taste by exploring new ingredients and technologies and optimizing the drug delivery method to enhance the patient experience.

CDMOs play a crucial role in enhancing syrup formulations' taste by using their extensive expertise in drug formulation and delivery. This has a significant impact on patient acceptability and medication adherence, ultimately leading to improved health outcomes.

 Akums Drug and Pharmaceuticals Ltd.

Akums Drug and Pharmaceuticals Ltd. is a worldwide fame earner Contract Development Manufacturing Organization (CDMO). Compliance with rules, standards, and requirements is known to be its specialty, and thus to ensure patient acceptance and compliance, fine and enhanced taste-masking procedures are used to cover up or eliminate the bitter or unpleasant taste of active medicinal ingredients/drugs. Meeting the requirements is best handled by Akums and thus it has a big clientele who believe in the quality and firm devoting Ly.

 Key Takeaways

·         Enhancing syrup formulations' taste for better patient acceptability  is required because the taste is an important factor in medication adherence.

·         CDMOs play a crucial role in enhancing syrup formulations' taste by  leveraging their extensive expertise in drug formulation and delivery.

·         Akums Drug and Pharmaceuticals Ltd. is a worldwide fame earner  Contract Development Manufacturing Organization (CDMO). Compliance with  rules, standards, and requirements is known to be its specialty

[global-research-report]

Microbial Fermentation Technology: Key Drivers, Challenges, and Market Opportunities

The global microbial fermentation technology market size is expected to reach USD 49.39 billion by 2030, registering a CAGR of 5.8% according to a new report by Grand View Research, Inc. Since fermentation is observed to be of utmost importance in the manufacturing of biopharmaceuticals, there is also a growing demand for microbial fermentation technology in biopharmaceutical manufacturing. This has led to increasing collaborations and developments in this market space.

For instance, in September 2021, BIOVECTRA and ABEC collaboratively announced that the latter company would provide CSR single-use microbial fermentation solutions to expand BIOVECTRA’s manufacturing capabilities. The newly installed solutions are expected to provide a faster turnaround time with high-growth microbial fermentation on large scale. Moreover, in September 2022, Cargill and Genomatica along with Cyclone Engineers are working on a project to scale up the bioreactor fermentation processing. This project is a part of the National Biotechnology and Biomanufacturing Initiative with a grant of USD 2.5 million.

Furthermore, technological advances in microbial fermentation platforms are also expected to supplement the market growth. For instance, several metabolic engineering approaches have been developed by researchers to enhance the performance of microbial cell factories used for the production of complex biologics or small molecules. Such continuous developments in this market space are likely to increase the adoption of this technology in biomanufacturing.

Additionally, various medications and vaccines, such as hormones, antibody fragments, and pneumococcal vaccines, are bio-manufactured using microbial fermentation techniques. Bacterial cells are often resistant to shear damage, enabling the use of high-shear radial impeller systems and high agitation rates. This gives the fermentors a high mass transfer potential, allowing them to accommodate fast metabolizing, high-cell density microbial cell cultivations and increasing the quantity of product that the bioprocesses can produce. Thus, with the increasing adoption of SUB fermentors for bacterial fermentation, the market is likely to witness significant growth in the coming years.

Microbial Fermentation Technology Market Report Highlights

Based on application, the antibiotics segment captured the highest market revenue share in 2021. Increasing research activities due to the rise of antibiotic-resistant microbes have positively impacted market growth

Owing to the faster and more stable growth pattern of microorganisms, the use of fermentation in small molecule synthesis is expected to witness lucrative growth throughout the forecast period

By end-users, CMOs and CDMOs accounted for a significant share in 2021. The capacity expansion by several CMOs and the growing trend of outsourcing is expected to propel the segment revenue generation

Asia Pacific dominated the market in 2021 owing to the high number of operating CMOs and the growing biopharmaceutical industry in countries such as India, Japan, and China

Furthermore, the demand for biologics and biopharmaceuticals is increasing in Japan. As a result, Japanese firms are undertaking various strategic initiatives to enhance their domestic biomanufacturing operations

North America is anticipated to witness the fastest growth throughout the forecast period owing to the presence of a well-established biopharmaceutical industry coupled with a high number of fermentation solution providers

Continuous efforts by key players to improve their product offerings are also contributing to North America’s regional market growth

Microbial Fermentation Technology Market Segmentation

Grand View Research has segmented the global microbial fermentation technology market report based on application, end-user, and region:

Microbial Fermentation Technology Application Outlook (Revenue, USD Million, 2018 - 2030)

Antibiotics

Probiotics Supplements

Monoclonal Antibodies

Recombinant Proteins

Biosimilars

Vaccines

Enzymes

Small Molecules

Others

Microbial Fermentation Technology End-user Outlook (Revenue, USD Million, 2018 - 2030)

Bio-Pharmaceutical Companies

Contract Research Organizations (CROs)

CMOs & CDMOs

Academic & Research Institutes

Microbial Fermentation Technology Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Key Players in Microbial Fermentation Technology Market

Biocon Ltd.

BioVectra Inc.

Danone UK

Hoffmann-La Roche AG

Koninklijke DSM NV

Lonza

Novozymes A/S

TerraVia Holdings, Inc.

BIOZEEN

Order a free sample PDF of the Microbial Fermentation Technology Market Intelligence Study, published by Grand View Research.

[octanexlabsin]

Contract Manufacturing : Reliable and High-Quality Production Solutions

OctaneX Labs offers contract manufacturing services to pharmaceutical companies seeking reliable and high-quality production solutions. Our state-of-the-art manufacturing facilities adhere to stringent quality control measures and regulatory guidelines, ensuring the highest standards of safety and efficacy.

[ashish098]

Transforming Pharmaceutical Manufacturing with Continuous Innovation

The pharmaceutical manufacturing industry has undergone a lot of change over the years, from simple manual processes to highly sophisticated systems. Innovation is now at the center of how medicines are developed, making the industry more efficient, adaptable, and patient-focused.

[pinnaclelifescience16]

How CDMO Companies Accelerate the Development and Production of Cancer Drugs

Cancer drugs are among the most complex and expensive medications to develop. Most cancer drugs are noticeably distinct from normal pharmaceuticals; they require specialized research, stringent testing, and advanced manufacturing techniques. Launching an oncology drug from discovery to the market is not just about having a promising molecule; it is about working fast, working smart, and navigating strict and narrow pathways to regulate the drug's entry to the market. That is where CDMO services come in, such as Pinnacle Life Sciences, which help pharmaceutical companies to deliver life-saving cancer treatments more quickly to patients. CDMO companies provide the infrastructure and expertise necessary for streamlining the process, ensuring faster and more efficient drug production. For a cancer drug manufacturing company, partnering with a CDMO can be a game-changer in meeting market demand efficiently. The Challenges in Oncology Drug Development To develop a cancer drug or a new cancer drug is not easy. The generic decade and billions are needed for this process. What causes delays? Regulatory hurdles begin with having fast-track review and clinical trial empowerment. Nonetheless, all cosmetics are subjected to six-stage and three-step procedures before getting into a state of compliance. Complex formulations: These cancer therapeutics - including biologics and ADCs - resort to high-precision formulation and production techniques. Supply chain: Sourcing raw materials for oncology drugs is very challenging, and substantive supply problems persist in drug development. Scaling from lab to market: Just because a drug has shown efficacy in early trials, it cannot be called ready for large-scale production. A transition from small batches to full-scale production is key and is oftentimes a bottleneck. How CDMOs Can Speed Things Up Pharmaceutical companies find credible solutions to their issues in the establishment of CDMO companies. Why? Because a CDMO provides a pool of expertise, infrastructure, and streamlined processes that help in the quick launch of drugs into the marketplace.

Faster Early Development Patients suffer from long-standing delays in getting new medicines into practical use. CDMO services like Pinnacle Life Science equip pharmaceutical companies with the highest degree of efficiency and superior capabilities. This allows drug developers to bypass years of in-house capability building and leverage CDMO expertise. Moreover, CDMO companies have pre-established relationships with regulatory agencies, which is particularly useful for securing clinical trial approval more smoothly and efficiently.

Handling Complex Formulations Newer cancer drugs like liposomal formulations, ADCs, and personalized cell therapies demand specialized formulation and manufacturing capabilities. Oncology medicine manufacturers in India specialize in dealing with these complex formulations to ensure drug stability, bioavailability, and route of delivery.

Navigating Regulatory Hurdles Regulatory approval could well serve as the break in the chain of staging cancer drug development. CDMO services provide an in-depth understanding of global regulations, ensuring compliance with the largest oncology pharmaceutical companies, including FDA and EMA guidelines. These CDMOs prepare the necessary documentation, calibrate GMP parameters, and mitigate potential risks that could otherwise delay approvals. For companies looking to expand internationally, a cancer drug manufacturing company with strong CDMO backing ensures smoother regulatory processes and compliance with multiple market entry requirements.

Scaling Up for Mass Production Find a CDMO to pay for scaling up once a drug clears clinicals, an important step toward eventual medical intervention. CDMOs can optimize manufacturing processes to support the quality, purity, and efficiency required at every production stage. Pinnacle Life Science, with state-of-the-art manufacturing facilities, performs both small-batch and large-scale commercial production with no compromise on quality.

Cost-Effective Manufacturing Setting up in-house oncology medicine manufacturers in India can cost hundreds of millions of dollars. Instead, pharmaceutical companies can choose to outsource manufacturing, maintaining focus on research and marketing. The benefits of contract manufacturing include cost savings through economies of scale, streamlined operations, and optimized raw material sourcing. The Role of CDMOs in Drug Innovation CDMOs not only accelerate processes in drug formulation but also promote innovation. Their technological expertise builds up new drug delivery technologies and enhances bioavailability whilst reducing side effects. The future of oncology is personalized medicine, and top oncology pharmaceutical companies are already leveraging CDMO partnerships for small-batch production, customized formulations, and advanced genetic testing. This approach benefits biotech startups with promising lead candidates that lack large-scale manufacturing resources. Why Pinnacle Life Science Stands Out From early-stage formulation through commercial production, Pinnacle Life Science provides large consolidators with the advanced manufacturing capabilities necessary to streamline the go-to-market process for breakthrough cancer therapies. By partnering with Pinnacle, drug developers can: Accelerate timelines by leveraging Pinnacle’s advanced manufacturing capabilities. Ensure regulatory compliance through expert-led documentation and quality control. Optimize formulation and production with cutting-edge technology and experienced teams. Reduce costs by outsourcing expensive infrastructure and operational expenses. The Future of Cancer Drug Manufacturing The demand for innovative cancer treatments is only going to increase. With advances in targeted therapies, immuno-oncology, and personalized medicine, the role of CDMO companies will continue to expand. Largest oncology pharmaceutical companies already rely on specialized CDMOs like Pinnacle Life Science to bring new therapies to market quickly and efficiently. An experienced cancer drug manufacturing company partnered with a top-tier CDMO ensures a competitive advantage, helping them launch life-saving treatments faster and more effectively. CDMOs have become indispensable players in the pharmaceutical ecosystem, shaping the future of cancer treatment with cutting-edge manufacturing and regulatory expertise.

[chemxpert]

Unlocking Industry Insights with Chemxpert Database: Agro,and API Databases

Chemxpert Database offers a comprehensive solution with specialized databases tailored for the agro, cosmetics, biotech, and API sectors. Our agro database provides essential agricultural insights, while the cosmetics database reveals critical data in beauty and personal care. Explore cutting-edge developments with our biotech database, and access vital information on Active Pharmaceutical Ingredients in the API database. Chemxpert Database empowers professionals across industries to make informed decisions and drive innovation.

[industrynewsupdates]

A Comprehensive Overview of Investigational New Drug CDMO Market Landscape

 The global investigational new drug CDMO market size is expected to reach USD 7.79 billion by 2030, registering a CAGR of 6.9% during the forecast period, according to a new report by Grand View Research, Inc. This is largely due to the increased R&D investments, along with stringent regulations pertaining to IND.

The U.S. FDA and the European Medicines Agency (EMA) are health authority bodies that regulate the use of investigational drugs in the U.S. and the European Union, respectively. In addition, investigational review boards (IRBs) in the U.S. and ethics committees (ECs) in the European Union must approve the use of drugs in humans.

It is the requirement of a federal law that a drug be the subject of an approved marketing application prior to it is distributed or transported across the state lines. Hence, sponsors aiming to conduct clinical studies that involve an IND should gain exemption from the FDA to permit the shipping of the investigational drug to clinical investigators in several states.

The pandemic has significantly impacted the global economy in 2020 and has an ongoing impact on various industries. However, the market for IND CDMO has benefited from the pandemic. Prior to COVID-19, prospective sponsors demanded facility audits to ensure CDMOs had the required capacity, equipment, and personnel to undertake their projects. Nowadays, CDMOs should find new ways to attract new sponsors, such as through videos, virtual reality, and other technologies that allow sponsors to virtually experience the site.

Gather more insights about the market drivers, restrains and growth of the Investigational New Drug CDMO Market

Investigational New Drug CDMO Market Report Highlights

• In terms of product, the small molecule segment dominated the market with a revenue share of 88.4% in 2023. This is largely due to the increasing number of small molecules in development. Besides, in 2019, the small molecules dominated the new drug approvals accounting for 79% of all the NME approvals

• Based on service, the contract development segment led the market in 2023. The contract development offers several benefits over in-house development of drugs, such as access to industry experts, less time to market, cost-effectiveness, and more focus on core competencies

• By end user, pharmaceutical companies accounted for the largest share in 2023. This is due to the changes in the pharmaceutical industry that have an impact on research and development strategies, which, in turn, influence new drug approval trends

• Asia Pacific to register the fastest growth rate of 7.8% over the forecast period. Due to the rapid growth of pharmaceutical firms and contract manufacturing organizations in developing countries, such as India and China, the region is likely to overtake Europe and North America in the near future.

Investigational New Drug CDMO Market Segmentation

Grand View Research has segmented the global investigational new drug CDMO market on the basis of product, service, end-use, and region:

Investigational New Drug CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

• Small Molecule

• Large Molecule

Investigational New Drug CDMO Service Outlook (Revenue, USD Million, 2018 - 2030)

• Contract Development

o Small Molecule

o Bioanalysis and DMPK Studies

o Toxicology Testing

o Pathology and Safety Pharmacology Studies

o Drug Substance Synthetic Route Development

o Drug Substance Process Development

o Form Selection Crystallization Process Development

o Scale-up of Drug Substance

o Pre Formulation

o Preclinical Formulation Selection

o First In Man Formulation/ Process Development

o Analytical Method Development / Validation

o Release Testing of Drug Substance and Drug Product

o Work Up Purification Steps

o Telescoping & Process Refining

o Initial Optimization

o Formal Stability of Drug Substance and Drug Product

o Large Molecule

o Cell Line Development

o Process Development

• Contract Manufacturing

o Small Molecule

o Large Molecule

Investigational New Drug CDMO End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical Companies

• Biotech Companies

• Others

Investigational New Drug CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

List of Key Players in the Investigational New Drug CDMO Market

• Catalent, Inc.

• Lonza

• Recipharm AB

• Siegfried Holding AG

• Patheon Inc.

• Covance

• IQVIA Holdings Inc.

• Cambrex Corporation

• Charles River Laboratories International, Inc.

• Syneous Health

Order a free sample PDF of the Investigational New Drug CDMO Market Intelligence Study, published by Grand View Research.

[cdmocroserives]